Karygar

Karygar is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule therapeutics that target nuclear transport mechanisms. Founded by the pioneers behind Karyopharm Therapeutics, the company leverages deep expertise in karyopherin biology to address unmet needs in oncology and other serious diseases. Their lead program, KRG-101, is a first-in-class inhibitor of Karyopherin alpha 2 (KPNA2) currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors. By modulating the trafficking of proteins between the nucleus and cytoplasm, Karygar aims to restore the activity of tumor suppressor proteins and other critical regulatory factors. The company is headquartered in Newton, Massachusetts, and operates as a private entity.